drug
burosumab
Marketedupdated 3mo agoby $RARE Ultragenyx Pharmaceutical Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying burosumab
- —Expanded Access to Burosumab
- phase2Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
- —A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
- phase3Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
- phase3Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
- phase3Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
- phase2Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
- phase2Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
News(1)
- Biotechs bring big launches and pharma rivalries into Q2 earnings periodWith the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.biospace · 14d ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that